Everolimus-Eluting Stents Improve Vascular Response in a Diabetic Animal Model

Circulation: Cardiovascular Interventions - United States
doi 10.1161/circinterventions.113.001023
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Role of Drug Eluting Stents in Diabetic Patients

Heart
Cardiovascular MedicineCardiology
2006English

Biodegradable-Polymer Biolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study

Texas Heart Institute Journal
MedicineCardiovascular MedicineCardiology
2016English

Initial Pathological Responses of Second-Generation Everolimus-Eluting Stents Implantation in Japanese Coronary Arteries: Comparison With First-Generation Sirolimus-Eluting Stents

Journal of Cardiology
Cardiovascular MedicineCardiology
2018English

Long-Term Comparison of Everolimus-Eluting Stents With Sirolimus- And Paclitaxel-Eluting Stents for Percutaneous Coronary Intervention of Saphenous Vein Grafts

EuroIntervention
MedicineCardiovascular MedicineCardiology
2014English

Chronic Total Occlusion Successfully Treated With a Bioresorbable Everolimus-Eluting Vascular Scaffold

Postepy w Kardiologii Interwencyjnej
Cardiovascular MedicineCardiology
2014English

Bioresorbable Vascular Stents and Drug-Eluting Stents in Treatment of Coronary Heart Disease: A Meta-Analysis

Journal of Cardiothoracic Surgery
CardiologyCardiovascular MedicineMedicinePulmonaryRespiratory MedicineSurgery
2020English

Clinical Outcomes of Bioabsorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: Two-Year Follow-Up of the DESSOLVE III Trial

EuroIntervention
MedicineCardiovascular MedicineCardiology
2020English

Pharmacokinetic Analysis After Implantation of Everolimus-Eluting Self-Expanding Stents in the Peripheral Vasculature

Journal of Vascular Surgery
SurgeryCardiovascular MedicineCardiology
2012English

Hybrid Coronary Percutaneous Treatment With Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-Years Results From the GABI-R Registry

Journal of Clinical Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy